Skip to main content
. 2020 Apr 7;2020(4):CD012946. doi: 10.1002/14651858.CD012946.pub2
Mandatory items Optional items
Methods
Study design
  • Parallel group RCT, i.e. people randomized to treatment

  • Within‐person RCT, i.e. eyes randomized to treatment

  • Cluster RCT, i.e. communities randomized to treatment

  • Cross‐over RCT

  • Other, specify

Exclusions after randomization
Losses to follow‐up
Number randomized/analyzed
How were missing data handled? e.g. available‐case analysis, imputation methods
Reported power calculation (Y/N), if yes, sample size and power
Unusual study design/issues
Eyes or unit of randomization/unit of analysis
  • One eye included in study, specify how eye selected

  • Two eyes included in study, both eyes received same treatment, briefly specify how analyzed (best/worst/average/both and adjusted for within person correlation/both and not adjusted for within person correlation) and specify if mixture one eye and two eyes

  • Two eyes included in study, eyes received different treatments, specify if correct pair‐matched analysis done

Participants
Country   Setting
Ethnic group
Equivalence of baseline characteristics (Y/N)
Total number of participants This information should be collected for total study population recruited into the study. If these data are only reported for the people who were followed up only, please indicate
Number (%) of men and women
Average age and age range
Inclusion criteria  
Exclusion criteria  
Interventions
Intervention (n = )
Comparator (n = )
See MECIR 65 and 70
  • Number of people randomized

  • Drug (or intervention) name

  • Dose

  • Frequency

  • Route of administration

 
Outcomes
Primary and secondary outcomes as defined in study reports
See MECIR R70
List outcomes
Adverse events reported (Y/N)
Length of follow‐up and intervals at which outcomes assessed
Planned/actual length of follow‐up